Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance

Abstract In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecu...

Descrición completa

Detalles Bibliográficos

Principais autores:	Naoki Okamoto, Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Kei Kawada, Yuki Izawa‐Ishizawa, Satoshi Sakaguchi, Keisuke Ishizawa
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2024-08-01
Series:	Pharmacology Research & Perspectives
Assuntos:	asciminib BCR‐ABL inhibitors chronic myelogenous leukemia drug resistance
Acceso en liña:	https://doi.org/10.1002/prp2.1214
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!